Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb. 28, 2023 |
Nov. 30, 2022 |
Aug. 31, 2022 |
Feb. 28, 2022 |
Nov. 30, 2021 |
Aug. 31, 2021 |
Feb. 28, 2021 |
Nov. 30, 2020 |
Nov. 30, 2021 |
Nov. 30, 2020 |
Feb. 28, 2023 |
Feb. 28, 2022 |
Feb. 28, 2021 |
May 31, 2022 |
May 31, 2021 |
May 31, 2020 |
|||||||||
| Summary Of Significant Accounting Policies [Line Items] | ||||||||||||||||||||||||
| Net loss | $ 13,702 | $ 26,495 | $ 20,991 | $ 41,285 | [1],[2] | $ 40,077 | [1] | $ 45,337 | [1] | $ 37,581 | $ 37,980 | $ 85,414 | $ 68,812 | $ 61,188 | $ 126,699 | [1],[2] | $ 106,393 | $ 210,820 | $ 176,465 | |||||
| Accumulated deficit | 823,054 | 681,622 | $ 639,940 | $ 599,432 | $ 483,183 | $ 445,191 | $ 639,940 | $ 445,191 | 823,054 | 681,622 | $ 483,183 | 766,131 | 553,675 | |||||||||||
| Restricted cash | 5,998 | 1,000 | [1] | 5,998 | 1,000 | [1] | ||||||||||||||||||
| Escrow Deposit | 900 | 900 | ||||||||||||||||||||||
| Charge to APIC due to warrant modification | 2,200 | |||||||||||||||||||||||
| Amortization of Debt Issuance Costs | 17 | $ 19 | [1] | 51 | $ 70 | [1] | 87 | 65 | ||||||||||||||||
| Warrant expirations deemed dividend | 5,400 | |||||||||||||||||||||||
| Balance in excess of federally insured limits | 4,000 | 33,700 | ||||||||||||||||||||||
| Intangible asset impairment charges | $ 0 | $ 10,000 | $ 0 | |||||||||||||||||||||
| Asset Pledged as Collateral | ||||||||||||||||||||||||
| Summary Of Significant Accounting Policies [Line Items] | ||||||||||||||||||||||||
| Amount of cash collateral to be relieved of amount currently pledged | 5,100 | 5,100 | ||||||||||||||||||||||
| Bulk Drug Substance | ||||||||||||||||||||||||
| Summary Of Significant Accounting Policies [Line Items] | ||||||||||||||||||||||||
| Shelf life | 4 years | |||||||||||||||||||||||
| Extended shelf life | 4 years | |||||||||||||||||||||||
| Surety Bond Backstop Agreement | ||||||||||||||||||||||||
| Summary Of Significant Accounting Policies [Line Items] | ||||||||||||||||||||||||
| Amount of cash collateral to be relieved of amount currently pledged | $ 5,100 | 5,100 | ||||||||||||||||||||||
| Amortization of Debt Issuance Costs | $ 400 | |||||||||||||||||||||||
| ||||||||||||||||||||||||
| X | ||||||||||
- Definition Extended Shelf life of inventory, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Shelf life of inventory, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Summary Of Significant Accounting Policies [Line Items] No definition available.
|
| X | ||||||||||
- Definition Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of amortization expense attributable to debt issuance costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. No definition available.
|
| X | ||||||||||
- Definition Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement. No definition available.
|
| X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|